Compare GSK plc (GSK) vs PubMatic Inc (PUBM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs PubMatic Inc — how do they compare? GSK plc trades at $46.61 (market cap $91.88B), while PubMatic Inc trades at $18.77 (market cap $850.88M). The key difference: GSK plc is far larger — about 108× PubMatic Inc's market cap, and GSK plc pays a 3.9% dividend while PubMatic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and PubMatic Inc for 40 Days on average.
| GSK | PUBM | |
|---|---|---|
Market Cap | $91.88B | $850.88M |
Volume | 7,730,529 | 997,698 |
Sector | Health | Technology |
52-Week High | $61.18 | $19.18 |
52-Week Low | $43.24 | $6.28 |
Typical Hold Time | 93 Days | 40 Days |
Enterprise Value | $111.88B | $754.01M |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
PubMatic (PUBM) trades at $19.02, up 2.42% with a bullish technical signal and strong analyst consensus. The company shows mixed fundamentals with negative net income margins but positive cash flow and recent earnings beats. Recent Q2 2026 results exceeded expectations with 11% revenue growth, driven by mobile app and CTV segments. Technical indicators show bullish moving averages with neutral oscillators, while support sits at $18 and resistance at $19.
The outlook remains cautiously optimistic with 64.7% analyst buy ratings and a $19.89 price target. Key opportunities include AI-driven ad growth and market share gains, while risks involve persistent profitability challenges and competitive pressures in digital advertising. The CFO's planned retirement adds transitional uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →
